Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes PharmaphorumAstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.Metabolic & GLP-1Read full story pharminent June 9, 2026 (Last updated: June 11, 2026) Pharmaphorum AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer’s Hympavzi secures FDA expanded indications for haemophiliaNext: ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
